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T helper 17 (TH17) is a novel subset of T helper cells that has recently been identified in the hepatocellular carcinoma (HCC) tumor
environment. Its presence seems to be linked with HCC progression, possibly via facilitating angiogenesis. The origin of tumor-
associated TH17 may be related to the gut, in which the differentiation of T cells, especially TH17 cells, is affected by microbiota.
As TH17 may appear to be a new therapeutic target against tumor-promoting inflammation, strategies such as using probiotics to
polarize the response away from TH17 may be beneficial to slow down tumor progression. This paper will attempt to discuss the
potential linkage between HCC progression, TH17, and gut microbiota and the possible therapeutic implications of probiotics to
modulate TH17-mediated response for tumor growth.
1. Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer worldwide and is characterized by poor prognosis [1].
Tumor progression has now been recognized as the product
of crosstalk between cancer cells and stromal cells, including
immune cells [2]. Immune status appears to be different
in distinct sites of the tumor [3]. The intratumoral region
is generally in an immunosuppressive state [3] it contains
dysfunctional antigen presenting cells, altered proportion
of effector to regulatory T cells, and an abundance of
immunosuppressive molecules, forming a network to facili-
tate immune evasion [4]. In contrast, the peritumoral stroma
is highly infiltrated with various immune cells that actively
secrete high concentrations of inflammatory cytokines for
enhancing cell growth, angiogenesis, and tissue remodelling
[3]. Hence, inflammatory response has been suggested to
be rerouted in a tumor-promoting direction. Recently, TH17
cells have come into research focus as they have been
identified in a number of tumors including HCC. TH17,
and its effector molecules interleukin-17 (IL-17) and IL-22,
are potent inducers of tissue inflammation and have been
associated with a number of inflammatory and autoimmune
diseases [5, 6]. The role of TH17 is paradoxical, but now there
is accumulating evidence to illustrate that TH17 has tumor
promoting effects in some cancer such as HCC. Though
the origin of tumor associated TH17 cells is not completely
understood, it is possible that they are recruited from the
periphery [7]. The gut is the natural site of TH17 generation
and it has recently been found that microbes can affect
T cell differentiation via regulating dendritic cells. Thus,
there appears to be a complex relationship between HCC
progression, TH17 and gut microbiota. In this paper, the
potential linkage between these three factors and the possible
therapeutic implications of probiotics to modulate TH17-
mediated response for tumor growth will be discussed.
2. Relationship between IL-17-Producing
Cells and HCC Progression
IL-17 is a proinflammatory cytokine produced primarily by
a novel subset of CD4+T cells known as TH17. In addition
to TH cells, this cytokine can also be secreted by CD8+T
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cells, γδ T cells, lymphoid tissue inducer (LTi) cells, natural
killer (NK) cells, and granulocytes [8]. At present, the IL-
17-producing cells in human HCC tissue are found to be
from the adaptive arm of immunity. A majority of them were
identified to be TH17, though a substantial amount of IL-
17+CD8+T cells can also be found in tumor. In addition to
IL-17, these cells may also secrete IL-22, which was recently
found to be related to HCC as well, though its production is
not limited to T cells [9–11].
The role of TH17 cells in tumor immunity has been
controversial. However, several lines of evidence suggested
that these cells play a protumor role in HCC. Increased
levels of TH17 cells were found in tumor tissue [12] and
in peripheral blood [13] of HCC patients, and their level
is correlated with unfavorable disease outcomes [7, 12, 14].
Similar results have also been observed in animal models,
whereby limiting tumor TH17 expansion reduced the growth
of transplanted liver tumor in rodents [7].
Many functions of IL-17 in the tumormicroenvironment
contribute to tumor progression. Apart from a minor direct
effect on the proliferation and survival of cancer cells in
other systems [15], and the recent report on its role in
immune evasion via mediating B7-H1 expression on mono-
cytes to suppress cytotoxic T cell activity [13], the major
protumor role of IL-17 in inflammation-associated cancer
relies on fostering angiogenesis. Indeed, both animal and
human HCC tissues revealed that their levels were positively
correlated with microvessel density and that these cells were
observed to be enriched predominately at the invading edge
of tumor tissue, the site where angiogenesis is most active
[12]. The proangiogenic effect of IL-17 could be linked to
its interaction with various stromal cells such as fibroblasts,
keratinocytes, epithelial and endothelial cells. IL-17 leads to
the induction of IL-6, IL-8, prostaglandin (PG) E1, and PGE2
as well as enhancement of intercellular adhesion molecule-1
expression [16–19]. IL-17 also participates in mobilization
and recruitment of neutrophils [20] as well as inducing the
secretion of tumor necrosis factor-α (TNF-α) and IL-1β
from macrophages [21]. The collective effect results in the
release of an array of proangiogenic cytokines including vas-
cular endothelial growth factor (VEGF), hepatocyte growth
factor and keratinocyte-derived chemokine in the tumor
microenvironment [22]. Thus, IL-17 inevitably shifts the
local biologic balance toward a predominance of angiogenic
factors to enhance the net angiogenic activity. Owing to the
highly vascular nature of HCC, IL-17+ cells may play an
important role in progression of this type of tumor.
In addition to IL-17, it is conceivable that TH17 cell
promote HCC via IL-22 production as well. Though there
were only a few reports on the role of IL-22 in tumors,
the literature generally supported the tumor-promoting
function of this cytokine. A recent report from Jiang et al.
[10] illustrated the excessive expression of IL-22 in HCC
microenvironment and its expression appears to be related
to advanced cancer stages. Conversely, knockdown of IL-
22 inhibited tumor progression in a xenograft model of
other systems [23]. The tumor promoting effect of IL-22 is
believed to be mediated by signal transducer and activator of
transcription factor 3 (STAT3), an oncogenic transcription
factor constitutively activated in various malignancies [24].
In human liver cancer cells, IL-22-induced STAT3 activation
promoted at least three hallmarks of cancer (proliferation,
survival and angiogenesis) via the upregulation of a variety of
mitogenic (cyclin D1, c-myc, and Rb2), anti-apoptotic (Bcl-
2 and Bcl-xL) [10, 25], and angiogenic (VEGF) [10] genes.
IL-22 was also shown to have immunosuppressive functions
in other cancer [26], though it was not well studied in HCC
so far.
Since TH17 cells may act to promote HCC pathogenesis
via production of IL-17 and IL-22; if we can modulate the
TH17 status in the body, it may be possible to affect tumor
progression. In order to do this, we first need to know the
origin of tumor-associated TH17 cells.
3. Potential Source of Tumor-Associated
TH-17 Cells
Tumor-associated TH17 cells may either be induced in the
tumor microenvironment and/or recruited from distal sites.
In situ induction occurs when memory T cells enter
a site of inflammation and encounter activated antigen-
presenting cells (APC). Though it has been suggested that
tumor-associated-macrophage (TAM) may be responsible
for TH17 development because it outnumbers dendritic cells
(DC), the most efficient APC, in the tumor environment,
it appears that tumor-activated monocytes, but not TAM
may play a dominant role in TH17 expansion in the context
of HCC. Kuang et al. [7] have shown that monocytes
could be activated by liver cancer cells to secrete several
cytokines including IL-1β, IL-6, IL-23, thereby creating a
proinflammatory cytokine milieu that facilitates the in vitro
expansion of memory T cells. While studies in other systems
have also demonstrated a critical role of transforming growth
factor-β (TGF-β) in the development of human TH17 [27,
28], Kuang and his colleagues failed to find a correlation
between the expression of this cytokine and TH17 cell density,
implicating that the role of TGF-β in expanding TH17 cells
remains to be elucidated in the local tumor environment of
HCC. It is interesting to note that TH17 cells generated in
this cytokine milieu can also produce interferon-γ (IFN-γ),
which is the signature cytokine of TH1 cells. Thus there are
two subsets of TH cells in HCC tissue: TH17 (IL-17+ IFN-
γ−) and TH17/TH1 (IL-17+ IFN-γ+). How TH17/TH1 cells
are generated is not yet known but it is possible that the
tumor environment induces this phenotype, as most of the
circulating TH17 cells in HCC patients did not express IFN-
γ. IFN-γ from TH17/TH1 is suggested to promote further
recruitment of TH17 by inducing CCL20 expression. CCL20
is the ligand for CCR6, which is a receptor highly expressed
in the majority of TH17 cells [7, 29]. A positive feedback cycle
may be formed in the tissue environment: CCR6+ memory
TH17 is homed to tumor site by high levels of CCL20 [12].
It is then converted to TH17/TH1, which releases IFN-γ to
recruit more CCR6+ memory TH17 from the periphery pool
by the virtue of CCL20.
So where would the potential source for TH17 cells be?
TH17 cells are preferentially enriched in the intestinal lamina
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Figure 1: Polarization of T helper (TH) cell subsets. Naı¨ve CD4+
T cells develop into different lineages (TH1, TH2, TH17, and Treg)
in response to cytokine cues produced from antigen presenting
cells. IL: interleukin; interferon γ: IFN-γ; FOXP3: forkhead box
P3; RORγt: retinoic acid-related orphan receptor γt; STAT: signal
transducer and activator of transcription; β: TGF-β transforming
growth factor.
propria of ileum and colon, while very low frequencies of
these cells are present in extraintestinal sites at a steady
state [30–32]. Polarization of naı¨ve T cells is influenced by
diverse signals produced by APC to develop into distinct
effector (TH1, TH2, and TH17) or regulatory (Treg) lineages
(Figure 1). It is now recognized that IL-12 and IFN-γ are
needed for TH1 induction, whereas TH2 differentiation
requires IL-4, and Treg requires TGF-β [33]. For TH17
differentiation, in vitro studies show that it requires multiple
cytokines including TGF-β, IL-6, IL-21, IL-23, and IL-1β
[8, 34–38]. TGF-β induces the expression of the retinoic
acid-related orphan receptor RORγt, which is the master
transcription factor for the TH17 effector cell lineage [30].
However, TGF-β alone is unable to initiate TH17 differentia-
tion, as this cytokine also induces forkhead box p3 (Foxp3),
which is a transcription factor essential for the differentiation
of Tregs. Foxp3 would bind to RORγt and thereby inhibit
RORγt-directed IL-17 expression [39], and hence excess
TGF-β can inhibit expression and function of RORγt. In the
presence of proinflammatory cytokines such as IL-6 or IL-
21, this inhibitory effect would be relived, as these cytokines
activate STAT3 and suppress the expression of Foxp3. As a
result, the relative levels of RORγt are increased and TH17 cell
differentiation is promoted. Once TH17 cells have developed,
IL-23 is needed for stabilization and further expansion of
these cells, as illustrated by studies with IL-23 receptor-
deficient mice [40].
4. The Role of Microbiota in TH17 Immunity
Since IL-23 is required for developing productive and sus-
tained TH17 responses, the signals that induce the produc-
tion of this cytokinemight be critical in determining whether
TH17 cells dominated T cell response. Given that IL-23 is
mainly produced by innate immune cells, including DCs
and macrophages in the gut, it is not surprising to find that
signals from commensal bacteria is necessary for induction
of TH17 cells. This notion is supported by observation
where TH17 cells were absent in the sterile gut of newborn
mice but steadily increased from birth to post-weaning as
symbiotic bacteria gradually colonized the intestine [41].
More importantly, it is not general bacterial colonization but
the composition of bacteria that influence the makeup of
the lamina propria T lymphocyte subsets. Ivanov et al. [32]
has found that mice purchased from different vendors had
shown marked differences in the number of TH17 cells in the
gut. By sequencing microbiota of these animals, it was found
that TH17 cell responses appear to be induced by specific
classes of bacteria known as segmented filamentous bacteria
(SFB), a Gram-positive bacteria belonging to the Firmicutes
phylum and most closely related to the Clostridium genus
[42]. Prominent TH17 responses may also be seen upon
infection of pathogenic Mycobacterium [43], Klebsiella [44],
and Citrobacter [36] or upon colonization with a complex
microbial community [45]. Since multiple chronic liver
diseases including HCC are often associated with intestinal
dysbiosis and reduced species diversity [46–48], it seems
that gut-derived microbial signals and intestinal immune
network may be a factor to potentially reprogram systemic
immune response towards a tumor-promoting direction.
The mechanisms of how intestinal bacteria prime DC for
TH17 development is not yet fully understood, but it is likely
to involve several microbial-derived molecules such as the
toll-like receptor (TLR) ligands, adenosine 5′-triphosphate
(ATP), and serum amyloid A (SAA) that result in IL-23
production. TLRs are a class of pattern-recognition receptors
(PRRs) that play a key role in the innate immune system
for recognizing various microbes and/or its products, col-
lectively known as pathogen-associated molecular patterns
(PAMPs) [49]. The nature of cytokines secreted by DC is
dependent on PAMPs that DC encountered in the peripheral
tissues during its immature phase. While stimulation of
TLR4 by LPS gives both IL-23 and IL-12, stimulation of TLR2
by peptidoglycan generally induces large amounts of IL-23
from DC, though the quantity may vary depending on the
structure of peptidoglycan [50]. TLR9 and TLR5 signaling
may also be necessary, as illustrated by in vivo [51] and
in vitro [52] studies, respectively. Apart from PAMPs, the
binding of extracellular ATP could also elicit the release of
IL-23 in addition to other IL-17 inducing proinflammatory
cytokines such as IL-6 and IL-1β from DC [31, 53, 54]
as a result of activating the membrane ion channel and
G protein receptors such as ionotropic and metabotropic
purinergic receptors [55, 56]. The importance of the ATP
signaling pathway was demonstrated in vitro, whereby the
differentiation program of TH17 became severely inhibited
upon addition of ATP degrading enzyme apyrase [31].
Commensal bacteria have been shown to generate copious
amount of extracellular ATP [57] and thereby important in
IL-23 production. Transient production of IL-23 by lamina
propria DCs can also be induce by SAA, an acute phase
protein found to be upregulated in the ileum by TH17
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Figure 2: A simplified diagram showing the possible mechanisms of intestinal bacteria in influencing the polarization of TH17 cells in the
lamina propria. Activation of dendritic cells by intestinal microbes results in secretion of proinflammatory cytokines such as IL-12, L-23, IL-
27. TH17-inducing bacteria may promote TH17 immunity via IL-23 induction, which may involve signaling mediated by the TLR ligands (a),
extracellular ATP (b), and SAA (c). Meanwhile, some probiotic strains may skew immunity away from TH17 via IL-12 and IL-27 induction
as a result of activating TLR and dectin receptors (a′). These cytokines can inhibit TH17 development while facilitate TH1 differentiation.
Probioticmay also work by controlling the growth and colonization of TH17-inducing bacteria (d). IL: interleukin; P2X: ionotropic receptors;
P2Y: metabotropic receptors; PAMPs: pathogen-associated molecular patterns; SAA: serum amyloid A; TLR: toll-like receptor.
inducing bacteria. However, the signaling pathways induced
by SAA are currently unknown [58]. Collectively, these
findings illustrate that microbiota played an important role
in sustaining TH17 responses via IL-23 induction, which may
involve signaling mediated by the TLR ligand, ATP, and SAA.
This mechanism establishes a TH17 cell-inducing cytokine
environment (Figure 2).
5. Modulation of Extraintestinal TH17
Response by Commensal Bacteria
Notably, the influence of commensal bacteria on the balance
of T cell subsets is not only confined to the gut, but can
also be extended to extraintestinal sites. This notion may
be supported by several studies of autoimmune disease
whose development is TH17-dependent. It was found that
introduction of SFBs into the sterile gut of healthy mice was
able to induce arthritis and encephalomyelitis [59, 60]. The
aggravation of disease appeared to be the consequence of an
increase in the number of TH17 cells that traffic out of the
gut to the extraintestinal site, as Lee et al. [59] has revealed
an increase in TH17 cell responses in spinal cords of SFB
monocolonized mice in a model of encephalomyelitis. These
findings may have significant implications for regulating
systemic pathogenic TH17 by modulating the composition
of intestinal bacteria, and probiotics have been suggested to
exhibit this potential.
6. Potential Immunomodulatory
Capacity of Probiotics
Probiotics are live microorganisms that confer health benefit
to host when administered in adequate amounts [61].
The established probiotics are generally Lactobacillus and
Bifidobacterium species, though Lactococcus, Enterococcus,
and Streptococcus species, as well as some nonpathogenic
strains of Escherichia coli that can also be found [62].
Administration of Lactobacillus and Bifidobacterium species
orally has been shown to protect against the develop-
ment of various TH17-mediated diseases [63–72], possibly
via reprogramming TH cell response or by controlling
growth of TH17-inducing bacteria. Due to strain or species-
specific molecular characteristics of probiotic bacteria, the
immunomodulatory effect exhibited may depend strongly
on the choice of the probiotic strain.
Probiotic may prime DC for the development of other
TH subsets. For example, activation of TLR or dectin
receptors would trigger DC to produce IL-12p70, IL-23,
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or IL-27, which are important in skewing TH1 or TH17
immunity. While IL-23 sustains TH17 response, IL-12 and
IL-27 drive TH1 differentiation by activating STAT1 and
inducing the expression of T box transcription factor (T-
bet), the key transcriptional regulator of TH1 cells [5]. IL-
27 and IFN-γ derived from TH1 cells could downregulate
RORγt in a STAT1-dependent manner and thereby dampen
development of TH17 cells, whereas IL-17 from TH17 did
not similarly suppress TH1 polarization [73]. IL-12 and IFN-
γ would further increase T-bet expression in DC to drive
TH1 differentiation [74]. Hence, probiotic strain that favors
IL-12 and IL-27 is likely to skew immune response away
from TH17 to TH1 (Figure 2). Several strains of Lactobacillus
(e.g., L. acidophilus [75], L. gasseri [72], and L. rhamnosus
[76]) and Bifidobacterium (e.g., B. lactis, B. breve and B.
bifidum [77, 78]) may possess this capacity. TH1 cytokines
such as IL-12 and IFN-γ are known to have potent antitumor
immunity as they could activate cytotoxic T cells and NK
cells to kill cancer cells. Deficiency of T-bet in DC leads to
exaggerated TNF production and contributes to creating a
chronic inflammatory state that modulates the composition
of microbiota and eventually leads to cancer development
[79, 80]. Therefore, promoting TH1 differentiation by pro-
biotics may possibly shift pathogenic TH17 inflammation to
antitumor TH1 response.
Apart from regulating T cell polarization, probiotic may
also work by controlling the growth of TH17-inducing
bacteria such as SFB. Indeed, administration of L. plantarum
almost completely depleted the SFB present in the ileum
[81]. Although the underlying mechanisms have not yet been
investigated in that study, it is tempting to speculate that
probiotic may adversely affect SFB colonization and survival
by competing for the use of nutrients and other external
metabolites. In accordance to the highly reduced genome,
SFBs lack a number of enzymes for basic metabolic pathways
that are important for growth and survival, including biosyn-
thesis of amino acids and cofactors. To compensate for these
auxotrophies, SFB expressed a large array of transporters to
acquire sugars, many cofactors, and nearly all amino acids
and from the environment [82]. Lactobacillus may serve as
a competitor for the uptake of amino acids, as genome
sequencing has revealed a considerable degree of auxotrophy
for amino acids in these bacteria. There may also be
competition for the internalization and utilization of sugar,
as Bifidobacterium and Lactobacillus situated in intestinal
niche generally encode a large capacity for carbohydrate
transport and metabolism [83–87]. Bifidobacterium have
excellent carbohydrate sequestering capacity as they use
a “docking station” to capture carbohydrate to their cell
surface to avoid losing the molecules to nearby competitors
[88–90]. In addition to amino acids and sugar utilization,
the metabolism of some Lactobacillus strains, including
L. paracasei or L. rhamnosus, could also lead to major
changes to levels of a number of metabolites, including
methylamines and short-chain fatty acids [91, 92]. Together,
the metabolisms and activities of these commensal bacteria
may create an unfavorable environment for functionality
of SFB in vivo. Other strategies for probiotics to limit
pathogenic bacterial growth may include production of
antimicrobial compounds, competition for specific adhesion
sites and maintaining intestinal tight junction [81], but
these mechanisms will not be discussed here in detail. All
these mechanisms may directly or indirectly change the
composition and diversity of the intestinal microbiota and
modulate DC-mediated immunity as mentioned above.
All in all, commensal bacteria of Bifidobacterium and Lac-
tobacillus genera are associated with balancing TH response
locally and systemically. Hence, establishing a balanced
microbiota in favor of these protective probiotic bacteria
may be a good strategy to maintain immune homeostasis
via DC priming and that may possibly modulate tumorigenic
proinflammatory milieu at sites distant from the gut.
7. Conclusion
In conclusion, TH17 has recently been found in HCC tumor
and its presence has been linked to disease progression, possi-
bly involving angiogenesis. Gut TH17 seems to be a potential
source for tumor-associated TH17, where it could be homed
to the tumor environment via CCR6/CCL20 axis and expand
locally. Commensal bacteria are necessary for development
of gut TH17 by IL-23 induction in DC. Probiotics may affect
cytokine profile of DC by activating different PRRs and
controlling the growth of some potent TH17 inducers such
as SFB. This potential linkage of HCC environment, TH17
cells, and microbiota may implicate for novel targets for
therapeutic intervention in HCC progression.
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